Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2020-04-23 AGM Information
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
Biotec Pharmacon ASA - Notice of Annual General Meeting
AGM Information Classification · 98% confidence The document is explicitly titled "Biotec Pharmacon ASA - Notice of Annual General Meeting". It details the date, time, and location for the Annual General Meeting (AGM) and mentions that the notice, agenda, and appendices are attached. Since the document is a notice *about* the AGM, and not the presentation materials themselves, it aligns best with the AGM Information category (AGM-R). Although it is a notice, AGM-R is the most specific category for AGM-related documents, rather than the general RPA or RNS.
2020-04-23 English
Biotec Pharmacon Q1 2020 Presentation
Investor Presentation Classification · 98% confidence The document is titled 'Q1 2020 Presentation' and contains detailed financial highlights for the first quarter (Q1), including sales figures, EBITDA comparisons between 2020 and 2019, segment performance breakdowns (ArcticZymes, BetaGlucans), and updates on corporate strategy. This structure is characteristic of an Investor Presentation (IP) used to communicate periodic financial results and strategic direction to investors, distinct from a formal regulatory filing like a 10-K or a brief Earnings Release (ER). Although it covers Q1 financials, the depth and presentation format suggest it is the Investor Presentation accompanying or summarizing the period's results, rather than just the initial press release (ER). The document also contains a reminder for the AGM, but the primary content is the Q1 review.
2020-04-23 English
Biotec Pharmacon Q1 2020 Presentation
Investor Presentation Classification · 95% confidence The document text explicitly mentions 'Biotec Pharmacon Q1 2020 Presentation' and states that the company 'presents on April 23 2020 at 08:30 its interim report for the first quarter of 2020'. It also says, 'Please find the presentation attached.' This indicates the document is the presentation material itself, which is used to discuss the interim (quarterly) results. The most fitting category for a detailed presentation focusing on financials and strategy, especially one tied to an interim report, is Investor Presentation (IP). Although it relates to an interim report (IR), the format described is a presentation, not the comprehensive report itself.
2020-04-23 English
Biotec Pharmacon Q1 2020 Report
Earnings Release Classification · 95% confidence The document provides key financial highlights (sales, EBITDA, gross profit) and commentary from the CEO for the first quarter (Q1 2020). This structure—key figures, highlights, and management commentary—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (which would be an IR or 10-K), nor is it a transcript (CT) or a presentation (IP). The document explicitly states the results for the first quarter, making 'Interim / Quarterly Report' (IR) a possibility, but the format is brief, focusing on immediate results and highlights, which aligns better with the definition of an 'Earnings Release' (ER) which is the initial announcement of periodical financial results (key highlights only). The document also mentions that the full 'results, report and presentation' will be available elsewhere, reinforcing that this text itself is the initial announcement/release. Q1 2020
2020-04-23 English
Biotec Pharmacon Q1 2020 Report
Earnings Release Classification · 100% confidence The document is titled "Biotec Pharmacon Q1 2020 Report" and provides key financial highlights (sales, EBITDA, gross profit) for the first quarter of 2020, along with commentary from the CEO. This content structure—a summary of financial performance for a period shorter than a year—is characteristic of an Interim/Quarterly Report. Although it mentions a presentation and where the full report/presentation can be found, the core content provided is the summary of the results themselves, making it an Earnings Release (ER) or Interim Report (IR). Since it contains detailed financial metrics and commentary beyond just the initial highlights, it leans towards a comprehensive quarterly report rather than just a brief ER. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). Q1 2020
2020-04-23 English
Biotec Pharmacon ASA appoints Dr. Jethro Holter as CEO
Board/Management Information Classification · 99% confidence The document is a press release announcing a significant change in senior management: the appointment of Dr. Jethro Holter as the permanent Chief Executive Officer (CEO) after serving as interim CEO. This directly aligns with the definition for Board/Management Information (MANG), which covers the announcement of changes in the company's board of directors or senior management.
2020-04-22 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.